July 16 (Reuters) - CanSino Biologics Inc :
* SEES A NET PROFIT ATTRIBUTABLE OF ABOUT RMB900.0 MILLION TO RMB1,050.0 MILLION FOR SIX MONTHS
* SEES A REVENUE OF ABOUT RMB2,000.0 MILLION TO RMB2,200.0 MILLION FOR HY
* EXPECTED RESULT DUE TO INCREASED SALES OF RECOMBINANT NOVEL CORONAVIRUS VACCINE CONVIDECIA IN CHINA AND ABROAD
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
精彩评论